Cytel | Joshua Schultz

Counting on Capital: Private Equity Perspectives

In our fourth episode of the Portfolio Perspective we interview Joshua Shultz, CEO of Cytel, a company dedicated to shaping the future of drug development.  

Join us as we discuss Cytel's experience working with private equity, the future of drug development, and how Cytel is helping in the global race to find a vaccine. 


To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada